Teduglutide vs GLP-2

Teduglutide is GLP-2 with one amino-acid swap that protects it from DPP-4, extending its action. Native GLP-2 is the intestinal growth hormone it copies.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Teduglutide

A degradation-resistant analogue of glucagon-like peptide-2 (GLP-2), approved for short bowel syndrome.

BEST STUDIED FOR

Repair & immune

Read the cited profile →

🧪

GLP-2

A 33-amino-acid gut hormone co-secreted with GLP-1 that drives growth and repair of the intestinal lining.

BEST STUDIED FOR

Repair & immune

Read the cited profile →

SIDE BY SIDE

	Teduglutide	GLP-2
The key difference	DPP-4-resistant analogue, approved	Native hormone, short-lived
Class	Repair & immune	Repair & immune
Mechanism	GLP-2 is a gut hormone that promotes growth and maintenance of the intestinal lining.	GLP-2 is encoded next to GLP-1 in the proglucagon gene and released from intestinal L-cells after meals.
Status	Approved (EU/US) for short bowel syndrome in adults and children; real-world and paediatric evidence is accumulating.	Endogenous hormone and research target; the degradation-resistant analogue teduglutide is an approved medicine.
Reported safety signals	Because it is intestinotrophic, labelling and reviews discuss monitoring for polyp growth; the "double-edged sword" debate centres on this growth effect.	Because GLP-2 is intestinotrophic, its relationship with neoplasia has been systematically reviewed.
A key study	Reviews teduglutide as a GLP-2 analogue that increases intestinal absorption in short bowel syndrome. (Drugs 2017, PMID 28194723)	Describes GLP-2 as a 33-amino-acid proglucagon product promoting nutrient absorption. (J Clin Endocrinol Metab 2001, PMID 11297614)

WHEN TO RESEARCH WHICH

GLP-2 for physiology; teduglutide for the approved therapeutic analogue. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Teduglutide] Teduglutide: A Review in Short Bowel Syndrome — Drugs 2017. PMID 28194723
[Teduglutide] Teduglutide: a review of its use in the treatment of patients with short bowel syndrome — Drugs 2013. PMID 23729002
[Teduglutide] Use of Teduglutide in Children With Intestinal Failure: A Systematic Review — Front Nutr 2022. PMID 35774551
[GLP-2] Glucagon-like peptide 2 — J Clin Endocrinol Metab 2001. PMID 11297614
[GLP-2] Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function — Compr Physiol 2018. PMID 29978894
[GLP-2] Glucagon like peptide-2 and neoplasia; a systematic review — Expert Rev Gastroenterol Hepatol 2018. PMID 29231791

FREQUENTLY ASKED

What is the difference between Teduglutide and GLP-2?

Teduglutide is GLP-2 with one amino-acid swap that protects it from DPP-4, extending its action. Native GLP-2 is the intestinal growth hormone it copies.

What is the regulatory status of Teduglutide and GLP-2?

Teduglutide: Approved (EU/US) for short bowel syndrome in adults and children; real-world and paediatric evidence is accumulating. GLP-2: Endogenous hormone and research target; the degradation-resistant analogue teduglutide is an approved medicine.

What safety signals have been reported?

Teduglutide: Because it is intestinotrophic, labelling and reviews discuss monitoring for polyp growth; the "double-edged sword" debate centres on this growth effect. GLP-2: Because GLP-2 is intestinotrophic, its relationship with neoplasia has been systematically reviewed.

Which studies is this comparison based on?

For Teduglutide: “Teduglutide: A Review in Short Bowel Syndrome” (PMID 28194723); “Teduglutide: a review of its use in the treatment of patients with short bowel syndrome” (PMID 23729002); “Use of Teduglutide in Children With Intestinal Failure: A Systematic Review” (PMID 35774551). For GLP-2: “Glucagon-like peptide 2” (PMID 11297614); “Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function” (PMID 29978894); “Glucagon like peptide-2 and neoplasia; a systematic review” (PMID 29231791).